Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji, et al.
Liver Cancer (2018) Vol. 8, Iss. 2, pp. 121-129
Open Access | Times Cited: 205

Showing 1-25 of 205 citing articles:

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 493
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Cancer Medicine (2019) Vol. 8, Iss. 8, pp. 3719-3728
Open Access | Times Cited: 153
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Cancer Medicine (2018) Vol. 8, Iss. 1, pp. 137-146
Open Access | Times Cited: 123
Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
Atsushi Hiraoka, Takashi Kumada, Kojiro Michitaka, et al.
Liver Cancer (2018) Vol. 8, Iss. 5, pp. 312-325
Open Access | Times Cited: 119
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Hepatology Research (2018) Vol. 49, Iss. 1, pp. 111-117
Open Access | Times Cited: 87
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 5, pp. 277-285
Closed Access | Times Cited: 80
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Liver International (2020) Vol. 40, Iss. 4, pp. 968-976
Closed Access | Times Cited: 73
The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma
Delia D’Avola, Alessandro Granito, Manuel de la Torre‐Aláez, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 5, pp. 1185-1198
Open Access | Times Cited: 66
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research (2022) Vol. 52, Iss. 9, pp. 773-783
Open Access | Times Cited: 56
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research (2022) Vol. 52, Iss. 7, pp. 630-640
Closed Access | Times Cited: 44
Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis
Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, et al.
Hypertension Research (2025)
Open Access | Times Cited: 1
A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
Guoqing Ouyang, Bin Yi, Guangdong Pan, et al.
Cancer Cell International (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 63
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 734-743
Open Access | Times Cited: 51
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 2, pp. 392-402
Open Access | Times Cited: 50
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, et al.
Cancers (2021) Vol. 13, Iss. 1, pp. 160-160
Open Access | Times Cited: 49
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2021) Vol. 11, Iss. 1, pp. 1-8
Open Access | Times Cited: 44
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 42
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
Chi-Jung Wu, Pei‐Chang Lee, Ya‐Wen Hung, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2631-2643
Open Access | Times Cited: 36
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Takashi Niizeki, Takayuki Tokunaga, Yuko Takami, et al.
Targeted Oncology (2022) Vol. 17, Iss. 6, pp. 643-653
Open Access | Times Cited: 31
Report of the 23rd nationwide follow‐up survey of primary liver cancer in Japan (2014–2015)
Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, et al.
Hepatology Research (2023) Vol. 53, Iss. 10, pp. 895-959
Open Access | Times Cited: 20
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Richard S. Finn, Ann‐Lii Cheng, et al.
Liver Cancer (2023) Vol. 12, Iss. 5, pp. 479-493
Open Access | Times Cited: 19
Impact of immune‐related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Keito Suzuki, Yutaka Yasui, Kaoru Tsuchiya, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 6, pp. 1183-1189
Closed Access | Times Cited: 6
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, et al.
JHEP Reports (2020) Vol. 3, Iss. 2, pp. 100215-100215
Open Access | Times Cited: 45
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 6, pp. 334-340
Closed Access | Times Cited: 44
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, et al.
Liver Cancer (2019) Vol. 9, Iss. 1, pp. 73-83
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top